These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36423446)

  • 1. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer.
    Westin SN; Fu S; Tsimberidou A; Piha-Paul S; Akhmedzhanov F; Yilmaz B; McQuinn L; Brink AL; Gong J; Leung CH; Lin H; Hong DS; Pant S; Carter B; Jazaeri A; Gershenson D; Sood AK; Coleman RL; Shah J; Meric-Bernstam F; Naing A
    Gynecol Oncol; 2023 Jan; 168():76-82. PubMed ID: 36423446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.
    Thein KZ; Piha-Paul SA; Tsimberidou A; Karp DD; Janku F; Zarifa A; Shah J; Milton DR; Bean S; McQuinn L; Gong J; Colen R; Carter BW; Subbiah V; Ogbonna DC; Pant S; Meric-Bernstam F; Naing A
    Invest New Drugs; 2021 Oct; 39(5):1357-1365. PubMed ID: 33909232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study.
    Thein KZ; Karp DD; Tsimberidou A; Gong J; Sulovic S; Shah J; Milton DR; Hong DS; Janku F; McQuinn L; Stephen BA; Colen R; Carter BW; Yap TA; Piha-Paul SA; Fu S; Meric-Bernstam F; Naing A
    Invest New Drugs; 2022 Apr; 40(2):290-299. PubMed ID: 34562230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer.
    Nelson BE; Saleem S; Damodaran S; Somaiah N; Piha-Paul S; Moore JA; Yilmaz B; Ogbonna D; Karp DD; Dumbrava E; Tsimberidou AM; Hong DS; Rodon Ahnert J; Milton DR; Zheng X; Booser DJ; Ibrahim NK; Conley AP; Bhosale P; Rojas Hernandez CM; Tripathy D; Naing A; Meric-Bernstam F
    Cancer; 2023 Jul; 129(14):2201-2213. PubMed ID: 37016732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers.
    Rubinstein MM; Grisham RN; Cadoo K; Kyi C; Tew WP; Friedman CF; O'Cearbhaill RE; Zamarin D; Zhou Q; Iasonos A; Nikolovski I; Xu H; Soldan KN; Caird I; Martin M; Guillen J; Eid KT; Aghajanian C; Makker V
    Gynecol Oncol; 2021 Jan; 160(1):71-76. PubMed ID: 33139041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
    Falchook G; Coleman RL; Roszak A; Behbakht K; Matulonis U; Ray-Coquard I; Sawrycki P; Duska LR; Tew W; Ghamande S; Lesoin A; Schwartz PE; Buscema J; Fabbro M; Lortholary A; Goff B; Kurzrock R; Martin LP; Gray HJ; Fu S; Sheldon-Waniga E; Lin HM; Venkatakrishnan K; Zhou X; Leonard EJ; Schilder RJ
    JAMA Oncol; 2019 Jan; 5(1):e183773. PubMed ID: 30347019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies.
    Vergote IB; Lund B; Peen U; Umajuridze Z; Mau-Sorensen M; Kranich A; Van Nieuwenhuysen E; Haslund C; Nottrup T; Han SN; Concin N; Unger TJ; Chai Y; Au N; Rashal T; Joshi A; Crochiere M; Landesman Y; Shah J; Shacham S; Kauffman M; Mirza MR
    Gynecol Oncol; 2020 Feb; 156(2):308-314. PubMed ID: 31822399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
    Coleman RL; Handley KF; Burger R; Molin GZD; Stagg R; Sood AK; Moore KN
    Gynecol Oncol; 2020 May; 157(2):386-391. PubMed ID: 32037195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 1b trial of selinexor, a first-in-class selective inhibitor of nuclear export (SINE), in combination with doxorubicin in patients with advanced soft tissue sarcomas (STS).
    Lewin J; Malone E; Al-Ezzi E; Fasih S; Pedersen P; Accardi S; Gupta A; Abdul Razak A
    Eur J Cancer; 2021 Feb; 144():360-367. PubMed ID: 33418486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients.
    Martínez Sánchez MP; Megías-Vericat JE; Rodríguez-Veiga R; Vives S; Bergua JM; Torrent A; Suárez-Varela S; Boluda B; Martínez-López J; Cano-Ferri I; Acuña-Cruz E; Torres-Miñana L; Martín-Herreros B; Serrano A; Sempere A; Barragán E; Sargas C; Sanz M; Martínez-Cuadrón D; Montesinos P;
    Ann Hematol; 2021 Jun; 100(6):1497-1508. PubMed ID: 33914097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial.
    Moreno V; Barretina-Ginesta MP; García-Donas J; Jayson GC; Roxburgh P; Vázquez RM; Michael A; Antón-Torres A; Brown R; Krige D; Champion B; McNeish I
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34893524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
    Oza A; Kaye S; Van Tornout J; Sessa C; Gore M; Naumann RW; Hirte H; Colombo N; Chen J; Gorla S; Poondru S; Singh M; Steinberg J; Yuen G; Banerjee S
    Gynecol Oncol; 2018 May; 149(2):275-282. PubMed ID: 29454514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma.
    Lassman AB; Wen PY; van den Bent MJ; Plotkin SR; Walenkamp AME; Green AL; Li K; Walker CJ; Chang H; Tamir S; Henegar L; Shen Y; Alvarez MJ; Califano A; Landesman Y; Kauffman MG; Shacham S; Mau-Sørensen M
    Clin Cancer Res; 2022 Feb; 28(3):452-460. PubMed ID: 34728525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia.
    Sweet K; Komrokji R; Padron E; Cubitt CL; Turner JG; Zhou J; List AF; Sallman DA; Dawson JL; Sullivan DM; Chavez J; Shah BD; Lancet JE
    Clin Cancer Res; 2020 Jan; 26(1):54-60. PubMed ID: 31636097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
    Jakubowiak AJ; Jasielec JK; Rosenbaum CA; Cole CE; Chari A; Mikhael J; Nam J; McIver A; Severson E; Stephens LA; Tinari K; Rosebeck S; Zimmerman TM; Hycner T; Turowski A; Karrison T; Zonder JA
    Br J Haematol; 2019 Aug; 186(4):549-560. PubMed ID: 31124580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
    Patel A; Kalachand R; Busschots S; Doherty B; Kapros E; Lawlor D; Hall N; Stordal BK
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD008766. PubMed ID: 35866378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer.
    Wei XX; Siegel AP; Aggarwal R; Lin AM; Friedlander TW; Fong L; Kim W; Louttit M; Chang E; Zhang L; Ryan CJ
    Oncologist; 2018 Jun; 23(6):656-e64. PubMed ID: 29487219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer.
    Chelariu-Raicu A; Nick A; Urban R; Gordinier M; Leuschner C; Bavisotto L; Molin GZD; Whisnant JK; Coleman RL
    Gynecol Oncol; 2021 Feb; 160(2):418-426. PubMed ID: 33243443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia.
    Chen C; Siegel D; Gutierrez M; Jacoby M; Hofmeister CC; Gabrail N; Baz R; Mau-Sorensen M; Berdeja JG; Savona M; Savoie L; Trudel S; Areethamsirikul N; Unger TJ; Rashal T; Hanke T; Kauffman M; Shacham S; Reece D
    Blood; 2018 Feb; 131(8):855-863. PubMed ID: 29203585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.